Mark McWilliams - Spectrascience New Independent Chairman of the Board
Chairman
Mr. Mark D. McWilliams is an Independent Chairman of the Board of SpectraScience Inc. Mr. McWilliams has served as the CEO of Medipacs, Inc., a development stage infusion pump company. From December 2003 to November 2005, Mr. McWilliams was Director of Cell Imaging and Analysis at Beckman Coulter after the sale of Q3DM to Beckman in December 2003. He was President and Chief Executive Officer and Director of Q3DM, from October 2001 to December 2003, a lifesciences startup that raised several angel and VC funding rounds that was acquired by Beckman Coulter. Previously, he was founder and COO of Medication Delivery Devices, an alternate care infusion systems company that was acquired by Baxter Healthcare in 1996. Mr. McWilliams served as a VP of Research and Development at Baxter Healthcare for three years following the sale of MDD. Prior to MDD, he served as Product Development Manager at the founding of Block Medical where he was responsible for bringing the companys first two FDA approved products rapidly to market. Block was sold to Hillenbrand Industries in 1991. He previously worked for Hughes Aircraft, Vacuum General and Martin Marietta since 2010.
| Age | 59 |
| Tenure | 14 years |
| Address | 11568 Sorrento Valley Road, San Diego, CA, United States, 92121 |
| Phone | 858 847 0200 |
| Web | https://www.spectrascience.com |
Spectrascience New Management Efficiency
The company has return on total asset (ROA) of (0.9247) % which means that it has lost $0.9247 on every $100 spent on assets. This is way below average. Spectrascience New's management efficiency ratios could be used to measure how well Spectrascience New manages its routine affairs as well as how well it operates its assets and liabilities. At present, Spectrascience New's Return On Equity is projected to slightly decrease based on the last few years of reporting. At present, Spectrascience New's Total Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 5.10, whereas Other Assets are forecasted to decline to about 88.4 K.Management Performance
| Return On Asset | -0.92 |
Spectrascience New Leadership Team
Elected by the shareholders, the Spectrascience New's board of directors comprises two types of representatives: Spectrascience New inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectrascience. The board's role is to monitor Spectrascience New's management team and ensure that shareholders' interests are well served. Spectrascience New's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectrascience New's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark McWilliams, Independent Chairman of the Board | ||
| Rand Mulford, Director | ||
| Stanley Pappelbaum, Independent Director | ||
| Lowell Giffhorn, CFO, Principal Accounting Officer and Secretary | ||
| Michael Oliver, CEO and President COO and Director | ||
| Sheldon Miller, Independent Director | ||
| Duwaine Townsen, Independent Director |
Spectrascience Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spectrascience New a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.92 | ||||
| Current Valuation | 7.92 M | ||||
| Shares Outstanding | 4.92 B | ||||
| Price To Earning | (0.04) X | ||||
| Price To Sales | 73.07 X | ||||
| Revenue | 5.15 K | ||||
| Gross Profit | (194.25 K) | ||||
| EBITDA | (1.99 M) | ||||
| Net Income | (4.47 M) | ||||
| Cash And Equivalents | 27.88 K |
Currently Active Assets on Macroaxis
When determining whether Spectrascience New is a strong investment it is important to analyze Spectrascience New's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spectrascience New's future performance. For an informed investment choice regarding Spectrascience Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spectrascience New. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Spectrascience Stock analysis
When running Spectrascience New's price analysis, check to measure Spectrascience New's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spectrascience New is operating at the current time. Most of Spectrascience New's value examination focuses on studying past and present price action to predict the probability of Spectrascience New's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spectrascience New's price. Additionally, you may evaluate how the addition of Spectrascience New to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Spectrascience New's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spectrascience New. If investors know Spectrascience will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spectrascience New listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Return On Assets (0.92) |
The market value of Spectrascience New is measured differently than its book value, which is the value of Spectrascience that is recorded on the company's balance sheet. Investors also form their own opinion of Spectrascience New's value that differs from its market value or its book value, called intrinsic value, which is Spectrascience New's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spectrascience New's market value can be influenced by many factors that don't directly affect Spectrascience New's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spectrascience New's value and its price as these two are different measures arrived at by different means. Investors typically determine if Spectrascience New is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spectrascience New's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.